Drugs Reducing Cholesterol May Lower Risk of Alzheimer's Disease According to Recent Studies.

More broadly, researchers have been looking at the link between risk factors for heart disease, such as high cholesterol, and AD as highlighted by a recent story in Newsweek magazine (Jan 19, 2004, "Now, Reduce Your Risk of Alzheimer's; Intriguing New Studies Say the Same Measures That Help Your Heart Could Also Help Prevent Dementia"). The Newsweek story refers to the research of Dr. Larry Sparks, a leading researcher into the role of elevated cholesterol in Alzheimer's disease. At the Fourth Manhattan Alzheimer's Disease Conference, sponsored by Nymox, Dr. Sparks reviewed the results of his team's extensive studies supporting the potential value of statins in the treatment of AD.

Dr. Wolozin's paper reviews the many lines of evidence pointing towards a role for cholesterol in AD. The paper also points out that subjects with elevated mid-life cholesterol are at increased risk for AD.

The current global market for statins is estimated at $19 billion per year and to be growing at 15% per year. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting over 4 million people it is estimated in the U.S. alone.

"Effective methods of preventing or delaying the onset of Alzheimer's disease are urgently needed as our population ages," said Dr. Michael Munzar, Medical Director of Nymox. "Statins are well-known, widely prescribed medications with an excellent track record of safety and efficacy. They offer real potential for meeting the challenge of Alzheimer's disease."

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.